PMID- 12892873
OWN - NLM
STAT- MEDLINE
DCOM- 20040114
LR  - 20220311
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 63
IP  - 1-2
DP  - 2003 Sep 1
TI  - Acute and maintenance ECT with flupenthixol in refractory schizophrenia: 
      sustained improvements in psychopathology, quality of life, and social outcomes.
PG  - 189-93
AB  - OBJECTIVE: To determine the effects of ECT combined with antipsychotic medication 
      therapy on psychopathology, quality of life, and social functioning in patients 
      with refractory schizophrenia. METHOD: An open acute (Phase I) and maintenance 
      (Phase II) study of the combination of ECT and flupenthixol in the treatment of 
      46 schizophrenic patients who were nonresponsive to antipsychotic medication from 
      at least two different classes. Scales used: the Brief Psychiatric Rating Scale 
      (BPRS), the Quality of Life Scale (QLS), Social and Occupational Functioning 
      Assessment Scale (SOFAS), Global Assessment of Functioning (GAF), and Mini-Mental 
      State Exam (MMSE). The duration of Phase II was 1 year. RESULTS: In Phase I, 
      there were marked reductions in the BPRS scores, and substantial increases in the 
      QLS, SOFAS, GAF, and MMSE scores. During Phase II, the BPRS negative symptoms 
      worsened but remained improved from baseline. Changes in other outcome measures 
      were negligible. CONCLUSION: ECT and MECT combined with flupenthixol were 
      effective in improving psychopathology in patients refractory to antipsychotic 
      medication alone. Ratings of psychopathology, quality of life, and social 
      functioning all improved in Phase I and were generally sustained during Phase II 
      in patients who had remitted.
FAU - Chanpattana, Worrawat
AU  - Chanpattana W
AD  - Department of Psychiatry, Vajira Hospital, Srinakharinwirot University, 681 
      Samsen, Dusit, Bangkok 10300, Thailand. worch@loxinfo.co.th
FAU - Kramer, Barry Alan
AU  - Kramer BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - FA0UYH6QUO (Flupenthixol)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Brief Psychiatric Rating Scale
MH  - Combined Modality Therapy
MH  - *Electroconvulsive Therapy
MH  - Female
MH  - Flupenthixol/*therapeutic use
MH  - Humans
MH  - Male
MH  - *Quality of Life
MH  - Schizophrenia/diagnosis/drug therapy/*therapy
MH  - Severity of Illness Index
MH  - *Social Adjustment
MH  - Treatment Outcome
EDAT- 2003/08/02 05:00
MHDA- 2004/01/15 05:00
CRDT- 2003/08/02 05:00
PHST- 2003/08/02 05:00 [pubmed]
PHST- 2004/01/15 05:00 [medline]
PHST- 2003/08/02 05:00 [entrez]
AID - S0920996402003304 [pii]
AID - 10.1016/s0920-9964(02)00330-4 [doi]
PST - ppublish
SO  - Schizophr Res. 2003 Sep 1;63(1-2):189-93. doi: 10.1016/s0920-9964(02)00330-4.